Affirm (AFRM) stock steadies near $82 as CPI and the Fed crowd next week’s calendar
11 January 2026
1 min read

Affirm (AFRM) stock steadies near $82 as CPI and the Fed crowd next week’s calendar

New York, January 10, 2026, 18:05 EST — Market closed

  • AFRM ended Friday up roughly 0.2%, closing at $81.80, with the $80 level continuing to serve as a key near-term pivot.
  • After Friday’s jobs report, rate expectations are once again in the spotlight; U.S. CPI data is set for release Tuesday
  • Upcoming events to watch: the Fed’s Jan. 27-28 meeting and Affirm’s earnings report, due early February

Shares of Affirm Holdings Inc (AFRM.O) edged up 0.2% to close Friday at $81.80, after moving between $79.83 and $82.99 during the session. The buy now, pay later lender remains roughly 18% below its 52-week peak of $100. 1

The rate story is back in focus for Affirm and other consumer-credit stocks. The Labor Department reported payrolls climbed by 50,000 in December, while the unemployment rate dipped to 4.4%. This mix has left investors uncertain about the next interest rate move. “The market is going to be looking forward to what’s going to happen with interest rates and earnings,” said Adam Sarhan, CEO of 50 Park Investments. 2

Tuesday’s consumer price index report for December is now the key macro data to watch. The Bureau of Labor Statistics plans to release the CPI at 8:30 a.m. ET on Jan. 13. 3

U.S. stocks closed the week on a strong note Friday, hitting new highs as the S&P 500 gained 0.65% and the Nasdaq composite rose 0.82%, Reuters reported. 4

TD Cowen analyst Moshe Orenbuch cut his price target on Affirm to $110 from $115 but held onto a Buy rating, TheFly reports. 5

The Fed has its next policy meeting slated for Jan. 27-28, a key date for rate-sensitive growth stocks that tend to react sharply to rising yields. 6

Affirm’s upcoming earnings report is slated for about Feb. 5, per Investing.com. 7

Investors are focused on gross merchandise volume — the total dollar value of purchases processed via Affirm’s platform — and any shifts in credit performance. Funding costs and the balance of promotional zero-interest offers also matter, as they can push margins up or down.

Affirm operates in a packed payments space, going head-to-head with Block’s Afterpay and PayPal’s installment options. Its stock tends to move more on shifts in fintech sentiment than on specific company developments.

The setup works both ways. If inflation ticks up and drives yields higher, or if consumer delinquencies rise, the stock could lose gains fast.

AFRM’s next major catalyst arrives with the U.S. CPI report, set for Jan. 13 at 8:30 a.m. ET.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Freeport-McMoRan stock jumps as copper deal talk swirls and brokers lift targets
Previous Story

Freeport-McMoRan stock jumps as copper deal talk swirls and brokers lift targets

Corning stock slides into the weekend as CPI and Jan. 28 earnings loom
Next Story

Corning stock slides into the weekend as CPI and Jan. 28 earnings loom

Go toTop